Re: USA ZHCLF investors
in response to
by
posted on
Nov 01, 2022 09:23AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Answer: Many of Zenith’s shareholders received shares of the Company as a result of the spin out by Resverlogix Corp. (TSX: RVX) on June 3, 2013. At the time of the spin out, Resverlogix shareholders received one share of Zenith Epigenetics Corp. for every Resverlogix share held with no additional cash outlay. Zenith Epigenetics Corp. subsequently changed its name to Zenith Capital Corp."
Note the name change.
Koo